
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte is set to dominate the pneumococcal vaccine market with its best-in-class next-gen PCV, and current clinical data and trial designs support this outlook. The company also has a diverse pipeline with potential in other disease indications. Although facing standard risks in the biotech industry, Vaxcyte's financials and product potential position it as a strong investment opportunity.
Bears say
Vaxcyte is a clinical-stage company with a promising product pipeline in development, however, it is still several years away from bringing a product to market. Additionally, while the recent expansion of the adult vaccination market is a positive development, competitors such as SP0202 from Sanofi may pose a threat in the future. The current valuation of the company is attractive, but may already be pricing in success for the Ph3 readout for VAX-31, limiting potential price appreciation for investors. Additionally, there may be some uncertainty surrounding the outcome of the VAX-31 Ph2 infant trial, which could impact investor confidence.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares